Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two randomized controlled trial(s). ^[1-2]
• Triptorelin 22.5 mg/24 week depot injections reduced testosterone levels by 29% (95% confidence interval (CI) 17.2-41.7) compared to subcapsular orchiectomy, with a higher proportion of men reaching testosterone levels below 20 ng/dL at both 12 weeks (97% vs 79%) and 48 weeks (100% vs 87%) (p <0.05).
• No other drugs were included for direct comparison in effectiveness against triptorelin, and no specific population subgroups were highlighted in relation to effectiveness outcomes.
• No significant differences were observed in fasting plasma glucose changes between triptorelin and orchiectomy groups (0.2 mmol/L, 95% CI -0.1, 0.4; P = 0.32). However, the orchiectomy group exhibited greater increases in total fat mass (+2.06 kg, 95% CI 0.55, 3.56), subcutaneous adipose tissue (SAT) (+133 cm³, 95% CI 22, 243), and weight (+3.30 kg, 95% CI 0.74, 5.87) at 48 weeks, with increases in fat mass linked to higher insulin resistance (P < 0.001).
• ADT, including both triptorelin and orchiectomy, resulted in increased fat mass, SAT, visceral adipose tissue (VAT), serum cholesterols (total, high-density lipoprotein and low-density lipoprotein), and insulin resistance measures, alongside a reduction in lean body mass (LBM) over time (all P < 0.05).
• There is no population types or subgroups information available in the reviewed studies.